Table 1.
Characteristics of recurrence and non-recurrence patients.
| Total | Recurrence | Non-recurrence | |
|---|---|---|---|
| No. of patients | 209 | 45 | 164 |
| Age (years), mean ± SD (range) | 66 ± 4.92 (53–76) | 66 ± 5.20 (59–76) | 66 ± 4.87 (53–76) |
| Preoperative PSA level (ng/ml), mean ± SD (range) | 11.26 ± 7.48 (0.1–47.7) | 14.21 ± 9.81 (2–47.7) | 10.49 ± 6.56 (0.1–47) |
| PSA density (ng/ml2), mean ± SD (range) | 0.19 ± 0.15 (0.001–1.11) | 0.26 ± 0.20 (0.05–1.11) | 0.17 ± 0.12 (0.001–0.92) |
| Gleason score at biopsy | |||
| 3+3 | 39 (18.7%) | 4 (1.9%) | 35 (16.7%) |
| 3+4 | 76 (36.4%) | 8 (3.8%) | 68 (32.5%) |
| 4+3 | 39 (18.7%) | 8 (3.8%) | 31 (14.8%) |
| 3+5 | 7 (3.3%) | 3 (1.4%) | 4 (1.9%) |
| 4+4 | 27 (12.9%) | 9 (4.3%) | 18 (8.6%) |
| 4+5 | 17 (8.1%) | 13 (6.2%) | 4 (1.9%) |
| 5+3 | 1 (0.5%) | – | 1 (0.5%) |
| 5+4 | 3 (1.4%) | – | 3 (1.4%) |
| PI-RADS | |||
| Benign | 8 (3.8%) | 1 (0.5%) | 7 (3.3%) |
| 3 | 17 (8.1%) | 1 (0.5%) | 16 (7.7%) |
| 4 | 45 (21.5%) | 4 (2%) | 41 (19.6%) |
| 5 | 131 (62.7%) | 35 (17%) | 96 (45.9%) |
| N/I* | 8 (3.8%) | 4 (1.9%) | 4 (1.9%) |
| Surgical margin | |||
| Negative | 126 (60.3%) | 11 (5.3%) | 115 (55.0%) |
| Positive | 81 (38.7%) | 32 (15.3%) | 49 (23.4%) |
| N/I | 2 (1.0%) | 2 (1.0%) | – |
| Gleason Score after RP | |||
| 3+3 | 5 (2.4%) | – | 5 (2.4%) |
| 3+4 | 101 (48.3%) | 2 (1.0%) | 99 (47.4%) |
| 4+3 | 34 (16.3%) | 7 (3.3%) | 27 (12.9%) |
| 3+5 | 19 (9.1%) | 7 (3.3%) | 12 (5.7%) |
| 4+4 | 3 (1.4%) | – | 3 (1.4%) |
| 4+5 | 45 (21.5%) | 27 (12.9%) | 18 (8.6%) |
| N/I | 2 (1.0%) | 2 (1.0%) | – |
| Vascular invasion | |||
| Negative | 185 (88.5%) | 31 (14.8%) | 154 (73.7%) |
| Positive | 16 (7.7%) | 10 (4.8%) | 6 (2.9%) |
| N/I | 8 (3.8%) | 4 (1.9%) | 4 (1.9%) |
| Lymph node involvement | |||
| Negative | 186 (89.0%) | 32 (15.3%) | 154 (73.7%) |
| Positive | 10 (4.8%) | 8 (3.8%) | 2 (1.0%) |
| N/I | 13 (6.2%) | 5 (2.4%) | 8 (3.8%) |
*
No information.